Health·2,839 stories
At the AACR meeting, Revolution Medicines highlighted its RAS inhibitor daraxonrasib’s promising frontline pancreatic cancer data while unveiling a new catalytic compound, RM‑055, that can strip phosp
A Chinese gene‑therapy trial for hereditary deafness has shown striking results—90% of participants, including children and a 32‑year‑old adult, reported marked hearing gains. Published in Nature, the
Researchers at the University of Southern Denmark and Odense University Hospital have identified a previously unknown bacteriophage inside the common gut bacterium Bacteroides fragilis that is markedl
As the United States juggles overseas wars and delicate diplomacy, the CDC’s Epidemic Intelligence Service—now 75 years old—has quietly built a nationwide cadre of 4,300+ disease detectives ready to r
While Barcelona's headlines have been dominated by football setbacks, a University of Barcelona team led by Marta Alegret and partnered with Uppsala University and CIBEROBN has shown that combining th
At the AACR meeting, Revolution Medicines reported that its next‑generation KRAS inhibitor daraxonrasib shows promising first‑line and combination activity in advanced pancreatic cancer, while the NCI
Kyverna Therapeutics reported that its one‑time personalized CAR‑T cell therapy boosted mobility and cut disability in patients with stiff person syndrome, a rare autoimmune disorder. The company will
At the AACR meeting, Revolution Medicines unveiled its KRAS inhibitor daraxonrasib, which more than doubled median overall survival for second‑line pancreatic cancer patients, adding six months of lif
In a Senate health appropriations hearing, bipartisan lawmakers questioned Health Secretary Robert F. Kennedy Jr. about his 2027 budget that would cut HHS by 12% and eliminate NIH, while four GOP doct
The Trump administration’s BALANCE pilot aimed to test Medicare coverage of obesity drugs at a $245‑per‑month price with a $50 senior copay, but insurers balked, forcing the government to fund the tre
American cocaine use has fallen to a fraction of its 1980s peak as a generational shift away from the drug coincides with surging interest in ketamine and psychedelics — even as overdose deaths climb
NASA’s Curiosity rover has identified a suite of organic molecules, including five never‑seen before, in a dried lakebed on Mars, suggesting complex carbon chemistry can survive for 3.5 billion years.
Tortugas Neuroscience, a U.S. startup, has raised $106 million to fast‑track two Chinese‑origin drugs for schizophrenia and tinnitus, plus two Japanese‑origin candidates for epilepsy and encephalopath
While headlines have focused on the seven‑week war and oil shipment delays, this opinion reveals that the U.S. health care system spends much of its effort revisiting clinical decisions after they occ
NYU Langone researchers have identified the transcription factor HOXD13 as a dual driver of melanoma—simultaneously fueling tumor blood vessel growth and suppressing T cell infiltration—pointing to co
University of Kent scientists have discovered that madecassic acid, a compound from the Asian medicinal herb Centella asiatica long used in Korean skincare, can halt the growth of antibiotic-resistant
Researchers at the Swedish University of Agricultural Sciences found that realistic levels of cocaine and its metabolite benzoylecgonine cause juvenile Atlantic salmon to swim farther and disperse mor
Stress isn’t a one‑size‑fits‑all villain; acute episodes trigger a rapid adrenaline‑cortisol cascade that can sharpen cognition and boost physical performance, while chronic exposure fuels heart disea
Revolution Medicines’ KRAS inhibitor daraxonrasib delivered encouraging results in pancreatic cancer, proving that the notorious KRAS target can finally be drugged. At the same time, Novo Nordisk’s or
Researchers at Biohub found that three everyday amino acids—methionine, arginine, and serine—when mixed with lipid nanoparticles, amplify mRNA delivery twenty‑fold and push CRISPR editing efficiency t
Curated health stories, every morning. Free.
No spam. Unsubscribe anytime.